title: Subject satisfaction with onabotulinumtoxinA treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure.
abstract: BACKGROUND
  Patient satisfaction with treatment is an important outcome in facial aesthetic medicine.
  
  
  OBJECTIVE
  To evaluate subject satisfaction with onabotulinumtoxinA treatment of glabellar lines (GL) and crow's feet lines (CFL) using the validated Facial Line Satisfaction Questionnaire (FLSQ).
  
  
  METHODS
  In this randomized double-blind study, subjects with moderate/severe GL and CFL received onabotulinumtoxinA (20 U, GL; 24 U, CFL) or placebo. Over 120 days, the following were assessed: satisfaction, achievement of treatment expectations, satisfaction with duration of treatment (FLSQ), severity of GL and CFL (Facial Wrinkle Scale [FWS]), and aesthetic improvement (Global Aesthetic Improvement Scale).
  
  
  RESULTS
  Satisfaction in the per-protocol population was significantly greater at Day 60 in the onabotulinumtoxinA group (n = 60) compared with placebo (n = 57) for GL (81.7% vs 0%; p < .001). Most subjects treated with onabotulinumtoxinA remained satisfied up to 120 days. Achievement of treatment expectations (86.7%; Day 60), satisfaction (81.7%; Day 60), and satisfaction with the duration of treatment (61.6%; Day 90) were significantly better with onabotulinumtoxinA than placebo (p < .001) for GL and CFL combined. Efficacy (FWS) and aesthetic improvement were observed in most subjects at Days 30 and 60, respectively.
  
  
  CONCLUSIONS
  High satisfaction rates are achieved and sustained in subjects treated with onabotulinumtoxinA for GL and CFL combined.
authors.affiliation: *Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada; †Division of Dermatology, University of Toronto, Toronto, Ontario, Canada; ‡Project Skin MD Ltd., Vancouver, British Columbia, Canada; §Division of Dermatology, McMaster University, Hamilton, Ontario, Canada; ‖Division of Dermatology, Women's College Hospital, Toronto, Ontario, Canada; ¶Peloton Advantage, Parsippany, New Jersey; #Allergan, Inc., Irvine, California.
authors.forename: Jason K
authors.initials: JK
authors.lastname: Rivers
authors.forename: Vince
authors.initials: V
authors.lastname: Bertucci
authors.forename: William
authors.initials: W
authors.lastname: McGillivray
authors.forename: Channy
authors.initials: C
authors.lastname: Muhn
authors.forename: Nathan
authors.initials: N
authors.lastname: Rosen
authors.forename: Nowell
authors.initials: N
authors.lastname: Solish
authors.forename: Barry M
authors.initials: BM
authors.lastname: Weichman
authors.forename: Sarah
authors.initials: S
authors.lastname: Wheeler
authors.forename: Selena R
authors.initials: SR
authors.lastname: Daniels
authors.forename: Conor J
authors.initials: CJ
authors.lastname: Gallagher
mesh_terms: D065087:Acetylcholine Release Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D019274:Botulinum Toxins, Type A / Q000009:adverse effects / Q000627:therapeutic use*; D003357:Cosmetic Techniques; D004311:Double-Blind Method; D004954:Esthetics; D005123:Eye; D005260:Female; D005546:Forehead; D006801:Humans; D008297:Male; D008875:Middle Aged; D063868:Patient Outcome Assessment; D017060:Patient Satisfaction; D015595:Skin Aging / Q000187:drug effects*; D011795:Surveys and Questionnaires; D013997:Time Factors
chemical_list: D065087:Acetylcholine Release Inhibitors; D019274:Botulinum Toxins, Type A